LOGIN  |  REGISTER
Astria Therapeutics
Assertio

GE HealthCare Technologies to Join the Nasdaq-100 Index® Beginning June 7, 2023

May 30, 2023 | Last Trade: US$82.72 0.96 1.17

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that GE HealthCare Technologies Inc. (Nasdaq: GEHC), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX), the Nasdaq-100 Equal Weighted Index (Nasdaq: NDXE), and the Nasdaq-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Wednesday, June 7, 2023. GE HealthCare Technologies Inc. will replace Fiserv, Inc. (Nasdaq: FISV) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. Fiserv, Inc. will also be removed from the Nasdaq-100 ESG Index (Nasdaq: NDXESG) prior to market open on Wednesday, June 7, 2023.

For more information about the company, go to https://www.gehealthcare.com/.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

Media Contact: Camille Stafford, Nasdaq
Issuer & Investor Contact:  Index Client Services, Nasdaq
  This email address is being protected from spambots. You need JavaScript enabled to view it. 

 


Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB